A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson's Disease (PD) Save

Date Added
December 19th, 2017
PRO Number
Pro00069638
Researcher
Vanessa Hinson

Silhouette
Keywords
Drug Studies, Movement Disorders, Parkinsons
Summary

The purpose of this study is to determine if a drug called Nilotinib is safe, if it can be tolerated by patients with PD and to learn if Nilotinib has the possibility of effectively treating PD symptoms. Nilotinib has been approved by the Food and Drug Administration (FDA) to treat certain types of cancer (leukemia) but is considered investigational in this study because it has not been approved for treating PD.

In this study, we are comparing two doses (150mg or 300mg) of Nilotinib to placebo (a pill that looks like the study drug but does not have any active medication in it, like a sugar pill). If you are eligible and choose to be in the study you will be randomly assigned to one of three groups, either:

? 150mg Nilotinib
or
? 300mg Nilotinib
or
? Placebo

All three groups will take two pills of the assigned type each day by mouth. ?Randomly' means that the group you are placed in is determined by chance (like tossing a coin). You will have a 2:1 chance of receiving Nilotinib. Neither you nor the researchers will know whether you are taking Nilotinib or placebo.

About 100 individuals will be interviewed and assessed, and 75 people will be asked to participate in this study at 25 clinics across the United States. Approximately 6 participants will be asked to participate in the study at MUSC.

Institution
MUSC
Recruitment Contact
Shonna Jenkins
843-792-9115
jenkisho@musc.edu

Kickboxing and Cognition in Parkinson's Disease Save

Date Added
July 22nd, 2016
PRO Number
Pro00054295
Researcher
Vanessa Hinson

Silhouette
Keywords
Exercise, Memory Loss, Parkinsons
Summary

You are invited to volunteer for a research study if you have been diagnosed with Parkinson's Disease (PD) Stage 1-3.

This study will examine whether a kickboxing regime called "Rock Steady Boxing" helps improve cognitive dysfunction (thinking problems) in subjects with Parkinson's disease. "Rock Steady Boxing" is a fairly recent intervention for PD exercise rehabilitation.This program incorporates elements of aerobic exercise, with range of motion, visual spatial awareness, endurance, speed, agility, voice strengthening, and cognitive tasks. Your are eligible to participate if you plan to undergo Rock Steady Boxing as part of your own personal health plan, or you have indicated that you exercise regularly, but you do not intend to start Rock Steady Boxing.

Institution
MUSC
Recruitment Contact
Amy Delambo
843-792 5543
delambo@musc.edu

Change_preferences

-- OR --

Create_login